中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
24期
48-50
,共3页
吴亦文%刘涛%刘四平%张运芳
吳亦文%劉濤%劉四平%張運芳
오역문%류도%류사평%장운방
晚期结直肠癌%健脾化湿方%生存期%生存状态
晚期結直腸癌%健脾化濕方%生存期%生存狀態
만기결직장암%건비화습방%생존기%생존상태
Jianpihuashi prescription%Advanced colorectal cancer%Survival period%Survival state
目的:探讨健脾化湿方干预晚期结直肠癌生存期及生存状态的临床疗效。方法选取我院2009年1月~2011年5月肿瘤科患者43例,随机分为研究组22例及对照组21例,对两组患者的生活质量, Karnofsky功能状态评分及肿瘤近期疗效进行比较。结果研究组患者平均生存时间及中位生存时间明显高于对照组,两组比较,差异有统计学意义(P<0.05)。两组的1年生存率差异不大(P>0.05),研究组的2年生存率及3年生存率明显高于对照组(P<0.05)。研究组的平均进展时间为(378.13±43.46)d,明显高于对照组的(289.35±37.68)d,两组比较,差异有统计学意义(P<0.05)。研究组治疗前后生活质量评分比较,差异有统计学意义(P<0.05)。治疗后研究组的生活质量评分明显低于对照组,两组比较,差异有统计学意义(P<0.05)。研究组的总有效率为22.73%,对照组为23.80%,两组比较,差异无统计学意义(P>0.05)。结论健脾化湿方对改善晚期结直肠癌患者的生存期和生存状态具有明显作用。
目的:探討健脾化濕方榦預晚期結直腸癌生存期及生存狀態的臨床療效。方法選取我院2009年1月~2011年5月腫瘤科患者43例,隨機分為研究組22例及對照組21例,對兩組患者的生活質量, Karnofsky功能狀態評分及腫瘤近期療效進行比較。結果研究組患者平均生存時間及中位生存時間明顯高于對照組,兩組比較,差異有統計學意義(P<0.05)。兩組的1年生存率差異不大(P>0.05),研究組的2年生存率及3年生存率明顯高于對照組(P<0.05)。研究組的平均進展時間為(378.13±43.46)d,明顯高于對照組的(289.35±37.68)d,兩組比較,差異有統計學意義(P<0.05)。研究組治療前後生活質量評分比較,差異有統計學意義(P<0.05)。治療後研究組的生活質量評分明顯低于對照組,兩組比較,差異有統計學意義(P<0.05)。研究組的總有效率為22.73%,對照組為23.80%,兩組比較,差異無統計學意義(P>0.05)。結論健脾化濕方對改善晚期結直腸癌患者的生存期和生存狀態具有明顯作用。
목적:탐토건비화습방간예만기결직장암생존기급생존상태적림상료효。방법선취아원2009년1월~2011년5월종류과환자43례,수궤분위연구조22례급대조조21례,대량조환자적생활질량, Karnofsky공능상태평분급종류근기료효진행비교。결과연구조환자평균생존시간급중위생존시간명현고우대조조,량조비교,차이유통계학의의(P<0.05)。량조적1년생존솔차이불대(P>0.05),연구조적2년생존솔급3년생존솔명현고우대조조(P<0.05)。연구조적평균진전시간위(378.13±43.46)d,명현고우대조조적(289.35±37.68)d,량조비교,차이유통계학의의(P<0.05)。연구조치료전후생활질량평분비교,차이유통계학의의(P<0.05)。치료후연구조적생활질량평분명현저우대조조,량조비교,차이유통계학의의(P<0.05)。연구조적총유효솔위22.73%,대조조위23.80%,량조비교,차이무통계학의의(P>0.05)。결론건비화습방대개선만기결직장암환자적생존기화생존상태구유명현작용。
Objective To explore clinical effect of jianpihuashi prescription in the intervention of survival period and survival state of advanced colorectal cancer. Methods 43 patients in tumor department of our hospital were selected from 2009 January to 2011 May, and randomly divided into study group of 22 cases and control group of 21 cases, the patients' quality of life, Karnofsky functional status score and short term effect of tumor in two groups were compared. Results The patient's average survival time and median survival time in study group was significantly higher than the control group, there was significant difference between two groups(P<0.05). There was no difference in 1 year survival rate between two groups(P>0.05), the 2 years survival rate and 3 years survival rate of the study group were significantly higher than those of the control group(P < 0.05). The average time for progress in study group[(378.13±43.46)d] was significantly higher than the control group[(289.35±37.68)d], there was significant difference between two groups(P<0.05). There was significant difference in the quality of life score of study group between before and after treatment, the difference was significant(P < 0.05). The quality of life score in study group after treatment was significantly lower than the control group(P < 0.05). The total efficiency of study group was 22.73 % , control group was 23.80 % , there was no significant difference between two groups(P > 0.05). Conclusion Jianpihuashi prescription has obvious effect of intervention on survival period and survival state in patients with advanced colorectal cancer.